Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Targeting innate immunity to treat long-term type 1 diabetes.

King CC.

Regen Med. 2012 Nov;7(6):753-4. No abstract available.

PMID:
23304723
2.

Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.

Pickup JC.

Diabetes Care. 2004 Mar;27(3):813-23. Review.

PMID:
14988310
3.

Is type II diabetes mellitus a disease of the innate immune system?

Pickup JC, Crook MA.

Diabetologia. 1998 Oct;41(10):1241-8. Review.

PMID:
9794114
4.

Complexities of targeting innate immunity to treat infection.

Brown KL, Cosseau C, Gardy JL, Hancock RE.

Trends Immunol. 2007 Jun;28(6):260-6. Epub 2007 Apr 30. Review.

PMID:
17468048
5.

Innate immunity and its role in type 1 diabetes.

Zipris D.

Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):326-31. doi: 10.1097/MED.0b013e3283073a46. Review.

PMID:
18594272
6.

Innate immunity in type 1 diabetes.

Zipris D.

Diabetes Metab Res Rev. 2011 Nov;27(8):824-9. doi: 10.1002/dmrr.1256.

PMID:
22069267
7.

The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity.

Bottazzi B, Garlanda C, Cotena A, Moalli F, Jaillon S, Deban L, Mantovani A.

Immunol Rev. 2009 Jan;227(1):9-18. doi: 10.1111/j.1600-065X.2008.00719.x. Review.

PMID:
19120471
8.

Is the origin of type 1 diabetes in the gut?

Vaarala O.

Immunol Cell Biol. 2012 Mar;90(3):271-6. doi: 10.1038/icb.2011.115. Epub 2012 Jan 31. Review.

PMID:
22290506
9.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
10.

A role for innate immunity in type 1 diabetes?

Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD.

Diabetes Metab Res Rev. 2003 Mar-Apr;19(2):89-100. Review.

PMID:
12673777
11.

Long-term treatment with a health product (Squina Diacylglyceryl Ether) enhances innate and adaptive immunity in mice.

Leung HY, Ko KM.

J Complement Integr Med. 2012 Nov 26;9. pii: /j/jcim.2012.9.issue-1/1553-3840.1631/1553-3840.1631.xml. doi: 10.1515/1553-3840.1631.

PMID:
23192054
12.

Innate immunity and the pathogenesis of type 1 diabetes.

Grieco FA, Vendrame F, Spagnuolo I, Dotta F.

Semin Immunopathol. 2011 Jan;33(1):57-66. doi: 10.1007/s00281-010-0206-z. Epub 2010 Apr 10. Review.

PMID:
20383637
13.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
14.
15.

Innate immunity, insulin resistance and type 2 diabetes.

Fernández-Real JM, Pickup JC.

Trends Endocrinol Metab. 2008 Jan;19(1):10-6. Epub 2007 Dec 21. Review.

PMID:
18082417
16.

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.

17.
18.

Intensive therapy for diabetes through influence on innate immune system.

Li ZZ, Liu JB, Li L, Jiao L, Chen L.

Med Hypotheses. 2009 Jun;72(6):675-6. doi: 10.1016/j.mehy.2009.01.028. Epub 2009 Mar 4.

PMID:
19264419
19.

The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility.

Garlanda C, Maina V, Cotena A, Moalli F.

J Reprod Immunol. 2009 Dec;83(1-2):128-33. doi: 10.1016/j.jri.2009.05.006. Epub 2009 Nov 8. Review.

PMID:
19900712
20.

Innate immunity, insulin resistance and type 2 diabetes.

Fernández-Real JM, Pickup JC.

Diabetologia. 2012 Feb;55(2):273-8. doi: 10.1007/s00125-011-2387-y. Epub 2011 Nov 30.

PMID:
22124608
Items per page

Supplemental Content

Write to the Help Desk